Occam Places General Counsel for Public Biopharma KalVista Pharmaceuticals

KalVista Pharmaceuticals (Nasdaq: KALV) is a late-stage clinical biopharmaceutical company that has developed a proprietary portfolio of novel, small-molecule protease inhibitors. In September 2023, Occam placed Brian Krex as its General Counsel as the company prepares for the approval and commercialization of its lead phase 3 program targeting hereditary angioedema (HAE). Previously, Brian served as General Counsel of Clover Biopharmaceuticals and AGTC. He was previously Head of Commercial and Regulatory Law at Alexion. Brian began his operating career at Pfizer, serving as lead commercial counsel for major franchises and several successful product launches. He came to Pfizer after six years in the healthcare practice of New York-based firm Moses & Singer. Brian holds a J.D. from Seton Hall University and a B.A. from Bard College.

‍

KalVista is a long-standing client for whom Occam has placed two leadership team members at different critical inflection points in the company’s growth. In 2021, Occam placed Paul Audhya as CMO, who brought medical affairs experience to an advanced clinical pipeline. Three years earlier, in 2016, Occam placed Ben Palleiko as CBO & CFO. Ben was promoted to President earlier this year to oversee the company’s growing commercial organization.